Skip to main content
. 2022 Jun 6;5(6):e2215589. doi: 10.1001/jamanetworkopen.2022.15589

Figure 1. Progression-Free Survival (PFS) and Overall Survival for Patients With NSCLC With or Without Driver Variations Treated With Definitive Chemoradiation and Consolidative Durvalumab.

Figure 1.

A, Median PFS time was 8.4 months for patients with driver variations vs 40.1 months in patients without driver variations (log-rank P < .001). B, Median PFS time was 8.4 months for the non–KRAS driver mutation group, 8.0 months for the KRAS driver mutation group, and 40.1 months for the non-driver mutation group (log-rank P = .001). C, Median OS time was 36.2 months for those with driver variations and was not achieved in those without driver variations (log-rank P = .24).